Despite the stock price drop, Novo Nordisk's operational performance remains strong, particularly in its diabetes and obesity treatments. Legal concerns over compounded versions of its products exist, but the company's brand trust and regulatory backing are expected to mitigate any long-term negative impacts. This suggests a potential positive short-term impact on the stock price as the market may recognize the company's strong fundamentals.